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Abstract
Background: Postpartum hemorrhage (PPH) is associated with maternal morbidity and mortality and has an
increasing incidence in high-resource countries, despite dissemination of guidelines, introduction of skills
training, and correction for risk factors. Current guidelines advise the administration, as fluid resuscitation, of
almost twice the amount of blood lost. This advice is not evidence-based and could potentially harm
patients.
Methods: All women attending the outpatient clinic who are eligible will be informed of the study; oral and
written informed consent will be obtained. Where there is more than 500 ml blood loss and ongoing bleeding, patients
will be randomized to care as usual, fluid resuscitation with 1.5–2 times the amount of blood loss or fluid resuscitation
with 0.75–1.0 times the blood loss. Blood loss will be assessed by weighing all draping. A blood sample, for determining
hemoglobin concentration, hematocrit, thrombocyte concentration, and conventional coagulation parameters will be
taken at the start of the study, after 60 min, and 12–18 h after delivery. In a subgroup of women, additional
thromboelastometric parameters will be obtained.
Discussion: Our hypothesis is that massive fluid administration might lead to a progression of bleeding due to
secondary coagulation disorders. In non-pregnant individuals with massive blood loss, restrictive fluid management has
been shown to prevent a progression to dilution coagulopathy. These data, however, cannot be extrapolated to women
in labor.
Our objective is to compare both resuscitation protocols in women with early, mild PPH (blood loss 500–750 ml) and
ongoing bleeding, taking as primary outcome measure the progression to severe PPH (blood loss > 1000 ml).
Trial registration: Netherlands Trial Register, NTR 3789. Registered on 11 January 2013.
Keywords: Postpartum hemorrhage, Randomized controlled trial, Restrictive fluid resuscitation, Liberal fluid resuscitation,
Hemostatic parameters
* Correspondence: pim.schol@mumc.nl
2Department of Obstetrics and Gynecology, Maastricht University Medical
Centre, P.O. 616, 6200 MD Maastricht, the Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
de Lange et al. Trials  (2018) 19:166 
https://doi.org/10.1186/s13063-018-2512-z
Background
Postpartum hemorrhage (PPH) is the main cause of ma-
ternal death worldwide and the main cause of severe
maternal morbidity in the Netherlands and other high-
resource countries. It is defined by the World Health
Organization as blood loss more than 500 ml in the first
24 h after childbirth [1]. Annually in the Netherlands,
more than 12,000 cases with more than 1000 ml of
blood loss are reported; in about 750 cases, more than
four units of packed cells, intensive care admittance or
extensive surgical intervention is needed [2]. In total,
33.7% of all women in labor will have more than 500 ml
blood loss, 5–13% [3, 4] of whom will experience blood
loss of more than 1000 ml and an additional 24.3% of
whom will have blood loss of 500 to 1000 ml [3].
Recent publications have shown an increasing trend in
PPH in different high-resource countries over the past
years [5]. This increase is not directly linked to an in-
crease in women with risk factors for PPH. Two retro-
spective studies, performed in Australia and Canada,
concluded that although the frequency of risk and pro-
tective factors for PPH changed during the study period,
correction for these factors did not alter the increasing
trends in PPH [6, 7].
This increasing trend in PPH is also observed in the
Netherlands, despite the introduction of national mea-
sures to improve care for this population [4, 8].
Despite the implementation of guidelines, regular
training, and obligatory courses, the incidence of PPH is
still rising, which is all the more reason to evaluate cur-
rently advised protocols for managing PPH. Conclusive
evidence for optimal hemostatic resuscitation in PPH is
lacking [9]. The Managing Obstetric Emergencies and
Trauma course and the Royal College of Obstetricians
and Gynaecologists instructions advise generous volume
resuscitation to restore blood volume and oxygen carry-
ing capacity: about twice the lost volume and up to 3.5 l
of fast fluid infusion in patients with unstable bleeding
[10, 11]. The Dutch guidelines advise to start volume re-
suscitation when there is profuse blood loss; the specific
amount is not quantified. This guideline is based on the
same (animal) studies mentioned later in this protocol
[12]. Volume resuscitation can be done with crystalloids,
colloids, or red blood cells in different volume strategies,
which all have advantages and disadvantages (see the
discussion for a more detailed outline). Our hypothesis
is that massive fluid administration might lead to a pro-
gression of bleeding due to secondary coagulation disor-
ders in women with PPH.
Methods and design
Aims
The aim of the Restrictive Versus Massive Fluid Resusci-
tation Strategy (REFILL) study is to determine whether
in women with early, mild PPH (blood loss 500–750 ml)
and ongoing blood loss, restrictive fluid resuscitation
strategy reduces progression to severe PPH (defined as
blood loss > 1000 ml) compared with care as usual. We
hypothesize that restrictive fluid resuscitation will lead
to a decrease in progression to severe PPH and therefore
a decrease in its adverse outcomes.
Participant’s criteria and recruitment
In this multicenter study, women with 500–750 ml
blood loss postpartum and ongoing bleeding will be eli-
gible for the study. The study will be performed in three
Dutch hospitals, two university hospitals (Maastricht
University Medical Center, Radboud University Medical
Center) and one regional teaching hospital (Zuyderland
Medical Center). The Maastricht Medical Center is the
coordinating center.
All women attending the outpatient clinic or admitted
to the ward and not in active labor who meet the inclu-
sion criteria (see further) will be informed about the
study by the treating physician or research nurse. Oral
and written informed consent will be obtained. When
women present at the labor ward, they will be asked to
confirm orally whether they still want to participate in
the study (see Fig. 1).
Inclusion criteria are:
 Pregnant and labor starting after 24 + 0 weeks
 Age ≥ 18 years
Informed consent
 Mentally competent, understanding Dutch language
Exclusion criteria are:
 Prophylactic or therapeutic anticoagulant therapy
(carbasalate calcium within the previous 10 days or
low molecular weight heparins within previous 48 h)
 Known congenital coagulation disorders
 Pre-eclampsia (higher risk of low plasma volume,
higher risk of volume overload)
 Antenatal diagnosis of placenta accreta, increta, or
percreta
 Contraindication for massive fluid therapy (e.g.
cardiac causes, systemic causes (Marfan), renal
causes, pulmonary failure)
Randomization, procedures, and collection of data
In women with more than 500 ml blood loss and on-
going blood loss, randomization takes place. Treatment
allocation is blinded by use of opaque and sealed enve-
lopes. The randomization is stratified per center, in
blocks of four and concealed, in an allocation of 1:1. The
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envelopes will be distributed per center by Maastricht
University Medical Center. The required randomization
envelopes will be quickly and easily accessible at the
labor ward. Participants will be randomized to either the
intervention group (receiving fluids at 0.75–1.0 times
the blood loss) or the control group, who will receive
care as usual (receiving fluids at 1.5–2.0× blood loss).
In women participating in the study, blood loss will
be measured by weighing the absorption towels after
childbirth, excluding the first one directly after giving
birth, as this will include amniotic fluid. In current
care, generous volume resuscitation is standard; this
consists of about twice the lost volume and 2 l fast
infusion in patients with unstable bleeding. Volume
resuscitation will primarily be done with a fast infu-
sion of crystalloids or Ringers lactate. In all women,
the first 2000 ml will consist of a fast infusion of
NaCl (0.9%) or Ringers lactate, or a combination of
the two.
At the stage of 500–750 ml blood loss, the study
protocol starts (t1). Intravenous access will be estab-
lished and a blood sample taken for testing
hemoglobin concentration, hematocrit, platelet count,
activated partial thromboplastin time, prothrombin
time, and fibrinogen concentration. Women delivering
in the Maastricht University Medical Centre ROTEM®
analysis (FIBTEM, APTEM, INTEM, EXTEM) will be
included. Hemodynamic parameters include blood
pressure and oxygen saturation, as measured using
continuous pulse oximetry.
Additional clinical parameters will guide management
and serve as a safety check. We aim to maintain systolic
blood pressure > 90 mmHg and diastolic blood pres-
sure > 50 mmHg, or a decrease of less than 20 mmHg.
The maternal heart rate should be less than 125 beats
per minute [13]. If these cut-off values are crossed, an
additional volume of 500 ml will be administered in
15 min, in both groups.
At t2, 45–60 min after the initial start of infusion, two
situations can occur:
1. The patient is stable, defined as normal ongoing
blood loss (< 1 full sanitary pad/h) with stable blood
pressure and pulse. At this point, we will take an
extra blood sample, to test for hemoglobin
concentration, hematocrit, platelets, activated partial
thromboplastin time, prothrombin time, and
fibrinogen concentration.
2. The patient is still bleeding, defined as > 100 ml/h. If
the blood loss is greater than one full sanitary pad
Fig. 1 SPIRIT flow diagram. *t1 at 500–750 cm
3, resuscitation within randomized protocol starts, blood withdrawal. **t2, 45–60 min after t1, second
blood withdrawal. ***t3 12–18 h after t1, third blood withdrawal. **** i.e. maternal age, ethnic background, parity (nulliparous or multiparous),
gestational age, obstetric history, length, weight, use of oxytocin, mode of delivery (vaginal delivery, instrumental delivery, or Cesarean section),
delivery of placenta (spontaneous or manual), life birth, and birth weight. ***** All different treatments to resolve the underlying cause of PPH
given to the patient will be registered, intensive care admittance, the need of four or more units of packed cells, embolization, and hysterectomy,
laboratory results at t1, t2, and t3
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per hour, the blood loss will be weighed again.
Laboratory tests for hemoglobin concentration,
hematocrit, and coagulation status will be done, as
part of regular care.
At t3, 12–18 h postpartum, the last blood sample
will be taken for hemoglobin concentration and
hematocrit analysis. This is part of regular care in
women with blood loss > 500 ml.
In the case of > 1500 ml blood loss, the study
protocol will be terminated and patients will be
treated according to local massive hemorrhage proto-
col. Blood samples will still be drawn and the patient
will be analyzed on an intention-to-treat basis.
Except for the fluid resuscitation, treatment of the
underlying cause of the PPH will be according to the
local and national protocol (Nederlandse Vereniging
voor Obstetrie en Gynaecologie (NVOG) guidelines)
in both groups, which will be noted in the clinical
chart and registered in the trial data. We expect this
to be similar in both groups. The NVOG guidelines
advise basal preventive measures to identify women
at high risk, consisting of: an active third stage of
labor consisting of pre-labor use of an intravenous
access and recently known and matched blood type,
weighing the amount of blood loss when the blood
loss seems profuse and a preventive administration
of 5 IU of oxytocin intravenously after childbirth and
before placental birth. In women at high risk of
PPH, an additional 10 IU oxytocin is administered in
a course of 4 h postpartum. The guidelines do yet
not recommend tranexamic acid in a preventive
setting. If oxytocin is ineffective, or only partially ef-
fective, sulprostone (500 μg in 30 min followed by
60–120 μg/h) or methylergometrine (0.2 mg
intravenously or intramuscular) is recommended. If
blood loss is more than 1000 ml or if more than
2000 ml crystalloids are given, the guidelines advise
blood testing (activated partial thromboplastin time,
prothrombin time, thrombocyte concentration,
fibrinogen concentration, or thromboelastometry, if
available) and correct deficiencies accordingly. In
expectation of the laboratory results, fibrinogen or
tranexamic acid may be administered. This
recommendation dates from after the start of the
study.
Other study parameters regarding obstetric history
and the current pregnancy will be collected from the
patient’s chart.
All data are collected and stored anonymously in
Maastricht Medical Center in a restricted access file. A
trial number assigned to each patient will be used in the
dataset to ensure anonymous data collection. These trial
numbers are stored securely and locked from the
dataset. Data will be imputed as soon as possible after
study participation. The dataset will be saved; data will
be marked separately by date of saving. Data will be
stored for 15 years. PS, NL, HS, and LS will have access
to final dataset.
Outcome measures
Primary objective
The primary objective is to establish whether in women
with early, mild PPH (blood loss 500–750 ml) a fluid re-
suscitation strategy with fluids 0.75–1.0 times the blood
loss reduces the progression to severe PPH (defined as
blood loss > 1000 ml), compared with fluid resuscitation
with fluids 1.5–2.0 times the blood loss.
Secondary objective
Secondary outcomes are: difference in hemoglobin con-
centration (mmol/l) 12–18 h postpartum (including dif-
ferences in hemoglobin < 5.0 mmol/l), differences in
transfusion requirements (defined as the number of
units of packed red blood cells, fresh frozen plasma,
thrombocytes, and fibrinogen needed), differences in the
amount of coagulopathies, defined as individually abnor-
mal laboratory results according to current treatment
protocols (meaning platelets < 50 × 10,9 fibrinogen con-
centration < 1 g/L and activated partial thromboplastin
time and prothrombin time > 1.5 × mean control).
Severe adverse outcomes will be registered. We define
serious adverse outcomes as intensive care admittance,
the need of four or more units of packed cells,
embolization, and hysterectomy [2].
Statistical analysis
The between-group difference in the proportion of
women progressing from early mild PPH to severe PPH
and its confidence interval will be calculated. Descriptive
analysis will be carried out for baseline characteristics,
i.e. maternal age, ethnic background, parity (nulliparous
or multiparous), gestational age, obstetric history, length,
weight, use of oxytocin, mode of delivery (vaginal deliv-
ery, instrumental delivery, or Cesarean section), delivery
of placenta (spontaneously or manual), live birth, and
birth weight. All different treatments to resolve the
underlying cause of PPH given to the patient will be reg-
istered. Severity parameters will be described, i.e. inten-
sive care admittance, the need of four or more units of
packed cells, embolization, or hysterectomy.
Total blood loss, transfusion need, and laboratory re-
sults will be compared by use of either Student’s t test
for continuous outcomes or the chi-square test for di-
chotomous outcomes. In the case of non-normality,
mathematical transformation will be carried out of con-
tinuous outcomes. In the case of large differences in im-
portant prognostic variables at baseline (which are
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unanticipated in view of the randomization), multivari-
able logistic or linear regression analysis will employed,
to control for these variables. Analysis will be by
intention to treat. Missing data will not be imputed by
use of multiple imputation. All data will be analyzed
using IBM SPSS 24.0 software.
Sample size calculation
With the current standard of care, about 30% of all
women will proceed from 500 ml to 1000 ml of blood
loss. With a reduction from 30% to 15% (beta 0.80, alpha
0.05), 2 × 118 (236) women will have to be included. We
aim to include 250 women, to compensate for loss to
follow up or incomplete data.
Safety concerns
A data safety monitoring board has been established to
perform ongoing safety surveillance and interim analyses
of the safety data. The board will be informed in any
case of a severe adverse event. The board is composed
of three independent physicians: Dr. NMAA Engels
(anesthetist), Dr. JM Middeldorp (gynecologist from a
hospital not involved in the trial), and Dr. A Kessels
(epidemiologist). Dr. NMAA Engels is chairman of the
board. Further details about the board are listed in a
separate charter, which is available on request.
The data safety monitoring board will meet by telecon-
ference after the first 2 × 25 patients have been treated
and after every 50 patients thereafter per group, and will
conduct an interim analysis on the primary objective
measure and the composite measure of severe outcome
events (maternal death, use of more than four units of
packed cells, intensive care admittance, embolization, or
operative intervention.) The formulas proposed by
Prochan, Lan and Wittes [14] will be used for the in-
terim analysis.
In the analysis conducted by the data safety moni-
toring board, a correction will be made for possible
confounders for the primary outcome, such as risk
factors for PPH and difference in combined severe
outcome. Should there be a statistical significant dif-
ference in severe adverse events between the inter-
vention and the control group that cannot be
accounted to other factors, such as selection bias in
small groups, the data safety monitoring board shall
decide whether the study should be continued. The
study could be terminated prematurely on the advice
of the data safety monitoring board if one of the
treatment protocols shows less progression to severe
blood loss and less maternal morbidity; in this case, it
is not ethically justified to continue the study. All
communications by the data safety monitoring board
are reported via email to HS and PS. The final decision to
terminate the trial on the advice of the data safety moni-
toring board lies with HS.
The trial is overseen by PS and HS. They are respon-
sible for all communications with participating hospitals
and local research nurses, and are also responsible for
communication with the data safety monitoring board,
the ethics committee, and the trial registration bureau.
Insurance policies are available to patients in case of
adverse outcomes with lasting effects due to the study
intervention.
Discussion
Postpartum hemorrhage is increasing in incidence in in-
dustrialized countries; there is no evidence-based man-
aging protocol regarding fluid resuscitation. Volume
resuscitation can be done with crystalloids, colloids, or
red blood cells, which all have advantages and disadvan-
tages. Resuscitation with crystalloid fluids means that
large amounts are needed, which may induce acidosis
and coagulopathy, the formation of interstitial edema
and impairment of the microcirculation [15]. Colloid
fluids, in particular synthetic colloids, such as hydro-
xyethyl starch solutions, may impair clot formation and
therefore increase blood loss [16, 17]. Furthermore, even
new-generation medium molecular weight hydroxyethyl
starch solutions disturb fibrin polymerization in patients
undergoing spine surgery [18]; the presence of hydro-
xyethyl starch solutions or gelatin solutions in patients
with fibrinolysis leads to faster clot disintegration [19].
Once 30–40% of the circulating blood volume is lost,
red blood cell replacement will be required. Red blood
cells cannot be used for massive fluid therapy and one
must be careful not to use uncrossmatched blood,
especially in young fertile women, because of the possi-
bility of irregular antibody formation and its effect on
future pregnancies.
Restrictive or permissive resuscitation has recently
been advocated as an alternative to the current standard
care. In animal studies, military settings, and studies of
non-pregnant trauma patients, controlled hypotensive
resuscitation has been investigated. These studies have
shown that there might be an advantage for a restrictive
fluid resuscitation strategy. However, there are few well-
performed randomized controlled trials. This might be
due to ethical concerns in life-threatening conditions,
but is nonetheless important to improve survival and
morbidity, relying on evidence-based medicine. Until re-
cently, high-volume fluid resuscitation strategies have
been used to reverse hemorrhagic shock by replacing
blood loss with intravenous fluid or transfusions. This
strategy has been the gold standard, even though it has
not been tested in prospective randomized clinical trials
and has considerable limitations and risks. Increasing
evidence has demonstrated that aggressive crystalloid-
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based resuscitation strategies are associated with cardiac
and pulmonary complications, gastro-intestinal dysmoti-
lity, coagulation disorders, and immunological and in-
flammatory mediator dysfunction. Aggressive fluid
administration increases arterial and venous pressures,
but aggravates the dilution of clotting factors and blood
viscosity, which results in increased hemorrhage volume,
decreased oxygen delivery, and decreased survival rates
[20]. Continued fluid administration and positive fluid
balances have not been shown to improve renal out-
comes and may worsen overall prognosis in acute kidney
failure [21]. Also, maintaining a high or “normal” blood
pressure in patients with uncontrolled hemorrhagic
shock can result in the “lethal triad” of hypothermia,
acidemia, and coagulopathy [22].
Theoretical concerns regarding the safety of restrictive
resuscitation are based on the possible harmful effects of
decreased oxygen delivery to the various tissues of the
body due to shock. Maintaining a blood pressure that is
too low could potentially result in inadequate perfusion
and subsequent organ failure. Intraoperative restrictive
resuscitation has been successfully used in several ani-
mal models [23]. The results of Lu et al. [24] showed
that aggressive fluid resuscitation to restore near-normal
mean arterial pressure of 80 mmHg during uncontrolled
hemorrhage induced massive blood loss and excessive
hemodilution. Controlled fluid resuscitation to maintain
mean arterial pressure of 40 mmHg in the presurgical
treatment of severe and uncontrolled hemorrhagic shock
decreased further blood loss, avoided excessive hemodi-
lution and coagulopathy, improved the early survival
rate, and reduced apoptosis of the visceral organs [24].
Two randomized controlled trials investigated restrict-
ive resuscitation protocols in trauma patients. The pre-
liminary results on 90 patients in a randomized
controlled trial conducted by Morrison et al. [25]
showed fewer early postoperative deaths and signifi-
cantly fewer blood product transfusions in the study
group, without differences in the incidence or severity of
coagulopathy, thrombocytopenia, or anemia. In this
study, the difference in mean arterial pressure between
both study groups was not statistically significant and
the actual mean arterial pressures for the two groups
were much more similar than might be expected based
on the target goals for resuscitation [25]. The final re-
sults of this trial, including results obtained with the tar-
geted 271 patients, have not been published yet. Dutton
et al. [26] found no significant difference in mortality
between the study groups in a trial in which maintaining
a systolic blood pressure > 100 mmHg was compared
with targeting a systolic blood pressure of 70 mmHg
[26]. One of the limitations of this study is that no
power analysis was performed before initiating the study
and determining the sample size (n = 110) Also, as in the
previously mentioned study, the proposed target blood
pressure in the study group was not achieved.
A retrospective analysis by Duke et al. [27] of trauma
patients showed an overall lower mortality rate, lower
intraoperative mortality, and a shorter hospital stay in
the restrictive resuscitation group. Despite the fact that
the groups were well-matched, the retrospective charac-
ter of the study is a limitation and bias cannot be ruled
out [27].
A prospective randomized pilot trial comparing con-
trolled resuscitation versus standard resuscitation in
hypotensive trauma patients demonstrated that con-
trolled resuscitation strategy can be successfully and
safely implemented in a civilian environment. The re-
sults showed a reduction of early crystalloid resuscita-
tion volume, but also an increase in early blood product
transfusion [28].
In all, these studies, there were difficulties in following
the study protocol strictly. This may be explained by the
fact that these studies were performed in an acute set-
ting and by the impossibility of blinding the treating cli-
nicians, who might be less familiar with restrictive
resuscitation.
In conclusion, there is little and contradictive evidence
for either aggressive or restrictive fluid resuscitation, and
it is very difficult to perform good clinical trials. This is
reflected in the latest guidelines. The European Society
of Anaesthesiology guidelines on management of severe
perioperative bleeding recommend avoidance of hyper-
volemia. Permissive hypotension is not mentioned, but
implementation of delayed or low-volume resuscitation
protocols is not yet recommended [29]. Conversely, the
updated European guidelines on management of bleed-
ing and coagulopathy following major trauma recom-
mend a target systolic blood pressure of 80 to 90 mmHg
until major bleeding has been stopped in the initial
phase following trauma without brain injury [30].
All these results, mainly obtained for trauma patients,
cannot be extrapolated to pregnant women during labor,
in view of the physiological hemodynamic and hemostatic
changes that occur in pregnancy [31, 32]. Plasma volume
increases up to 40% during pregnancy, whereas red blood
cell count only increases by 30%, cardiac output is in-
creased, and systolic and diastolic blood pressure decrease
slightly in the second trimester and elevate toward term
pregnancy. At the end of normal pregnancy, changes in
the coagulation and fibrinolytic system result in an appar-
ent hypercoagulable state [33–35] to minimize blood loss
at delivery. In patients with PPH, this equilibrium will be
altered and may lead to profound and rapid changes in
hemostasis. In some cases, the disruption of the coagula-
tion precedes delivery and may contribute significantly to
development of PPH [36]. Timely recognition and prompt
intervention are crucial for the successful management of
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PPH [37]. In non-pregnant individuals with massive blood
loss, restrictive fluid management has been shown to pre-
vent a progression to dilution coagulopathy [16–19].
In conducting this study, we hope to find the best
managing option for treating PPH and to achieve a
decrease in adverse outcomes by reducing the severity of
PPH.
Trial status
Protocol version 8, February 2015. Recruitment started
August 2014. The trial is ongoing; 179 out of the 250 pa-
tients have been enrolled in the study. A planned interim
analysis in October 2017 by the data safety monitoring
board showed no safety issues needing discontinuation
and a high likelihood that the hypothesis will be proven.
The trial will end if the 250 patients are reached or when
the data safety monitoring board intervenes after
planned interim analysis.
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